Avectas

About

Avectas is a cell engineering technology company based in Dublin, Ireland, specializing in non-viral delivery platforms for advanced cell therapies. Founded in 2012 by Dr. Michael Maguire and Dr. Shirley O'Dea, Avectas focuses on improving the efficiency and cost-effectiveness of gene-modified cell therapy manufacturing. The company employs 29 people, including a significant number of doctorate holders. The core offering of Avectas is Solupore, a proprietary non-viral cell engineering platform. Solupore streamlines the manufacturing process by consolidating multiple unit processes into a single consumable, allowing for the delivery of advanced molecules into various cell types. This technology enhances cell proliferation, reduces batch failure rates, and lowers costs associated with manual intervention and facility investments. Avectas aims to partner with leading cell and gene therapy businesses and academic institutions, particularly focusing on T cells for immuno-oncology applications. The company has secured significant funding and holds multiple patents in biotechnology and molecular biology.